CTYCity Therapeutics

US ExchangeHealth Care2026-10-16

Clinical-stage biotech developing next-gen RNAi therapeutics for thromboembolic diseases, Stargardt disease type 1, and anemia of chronic disease.

$—IPO price

—Raised

$22.4Day-1 close

13.56%Day-1 return

Clinical-stage biotech developing next-gen RNAi therapeutics for thromboembolic diseases, Stargardt disease type 1, and anemia of chronic disease.

Company description (source: StockAnalysis)

City Therapeutics is a clinical-stage biotechnology company developing the next generation of RNA interference (“RNAi”) therapeutics designed to silence the expression of disease-relevant proteins, with the aim of delivering meaningful and durable benefits for patients in need. Our current pipeline is focused on indications with significant unmet medical need, including thromboembolic diseases, Stargardt disease type 1, and anemia of chronic disease, where we believe disease biology supports RNAi-mediated knockdown as a differentiated approach ...

生物医药RNA疗法临床阶段

51CFO read: Requires FDA late-stage clinical filing experience, RNAi platform financial modeling, and pipeline valuation expertise.

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO is an investment banking team focused on the US market: US IPOs, reverse mergers, shell deals, SPAC and De-SPAC, SEC filings and post-listing follow-ons, run by one team from structure to opening bell. Free 30-minute listing-route diagnosis, answered within 24 hours.

Talk to us